1260614-73-0 Usage
Description
N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine, also known as Tofacitinib impurity N, is an enantiopure stereoisomer of the drug Tofacitinib (T528000). It is an impurity found in the Janus kinase 3 (Jak3) inhibitor, CP-690,550, which is known to inhibit selected members of the STE7 and STE20 subfamily of kinases. N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine plays a significant role in the pharmaceutical industry due to its potential interactions and effects on various biological processes.
Uses
Used in Pharmaceutical Industry:
N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine is used as an impurity in the development and production of Tofacitinib, a Jak3 inhibitor. Its presence in the drug may affect the overall efficacy and safety profile of the medication. Understanding and controlling the levels of this impurity are crucial for ensuring the quality and consistency of Tofacitinib as a therapeutic agent.
Used in Research and Development:
In the field of research and development, N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine serves as a valuable compound for studying the structure-activity relationships of Jak3 inhibitors. This knowledge can be applied to design and synthesize more potent and selective inhibitors, potentially leading to the development of novel therapeutic agents for various diseases.
Used in Quality Control and Regulatory Compliance:
N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine is used as a reference compound in the quality control and regulatory compliance processes for Tofacitinib. Its analysis and quantification help ensure that the drug meets the required standards for purity, safety, and efficacy, ultimately contributing to the overall success of the pharmaceutical product in the market.
Check Digit Verification of cas no
The CAS Registry Mumber 1260614-73-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,0,6,1 and 4 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1260614-73:
(9*1)+(8*2)+(7*6)+(6*0)+(5*6)+(4*1)+(3*4)+(2*7)+(1*3)=130
130 % 10 = 0
So 1260614-73-0 is a valid CAS Registry Number.
1260614-73-0Relevant articles and documents
Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
Jiang, Jian-Kang,Ghoreschi, Kamran,Deflorian, Francesca,Chen, Zhi,Perreira, Melissa,Pesu, Marko,Smith, Jeremy,Nguyen, Dac-Trung,Liu, Eric H.,Leister, William,Costanzi, Stefano,O'Shea, John J.,Thomas, Craig J.
supporting information; experimental part, p. 8012 - 8018 (2009/12/07)
Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.
